Department of the Army November 23, 2015 – Federal Register Recent Federal Regulation Documents

In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive, royalty-bearing, revocable license to US Provisional Patent Application 62/131,444, filed March 11, 2015, entitled, ``A method for developing malaria sporozoites in vitro'' to MalarVx, Inc., a for profit corporation, having a principal place of business at 307 Westlake Avenue North, Suite 200, Seattle, WA 98109.